# CMAB vs IMAB in Metastatic Prostate Cancer

> **NCT00255268** · PHASE4 · WITHDRAWN · sponsor: **AstraZeneca** · enrollment: 15 (estimated)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Goserelin
- **DRUG:** Bicalutamide

## Key facts

- **NCT ID:** NCT00255268
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2007-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00255268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00255268, "CMAB vs IMAB in Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00255268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*